Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Delivery
- Drugs
- Medical
- Pharmaceuticals
- Hormones
- Tobacco
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 260368
— an exclusive license, even as to Licensor, under the Licensed Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory, subject to rights already granted to a Third Party under the Development Agreement between Licensor and and the Third Party; and,
— a non-exclusive royalty-free license under the Future Licensor Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory.
Licensor will assign to Licensee the Trademarks.
The Trademark means the trademark applications and registrations for the mark MACROFLUX.
Microprojection System means a microprojection array having a plurality of microprojections which pierce at least through the outmost layer, i.e., the stratum comeum layer, of the skin.
Macroflux® transdermal microprojection delivery system provides unique benefits including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.
Macroflux
skin patch technology provides rapid and reproducible intracutaneous administration of dry-coated antigen. The depth of skin penetration targets skin immune cells; the quantity of antigen delivered can be controlled by formulation, patch wearing time, and system size. This novel needle-free patch technology may ultimately have broad applications for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.
IPSCIO Record ID: 260367
The proprietary transdermal drug delivery technology is known as transdermal microprojection patch technology for use with GLP-1 Receptor Agonist(s).
GLP-1 Receptor Agonist(s) means any substance that binds to the GLP-1 receptor in vitro and activates it, as measured by initiation of an increase in cAMP, with at least 10 fold higher potency than native glucagon. For the avoidance of doubt, native glucagon is not a GLP-1 receptor agonist according to this definition.
IPSCIO Record ID: 356972
Licensed Products means the Daily Product and any Product Patch with a New Dosing Duration.
Daily Product means a Product Patch which is intended to deliver PTH formulations to a patient one time each day.
New Dosing Duration shall be any dosing duration, other than once daily, with respect to a Product Patch or Licensed Product. For example, if a Licensed Product has an administration once daily, then a once weekly administration would be a New Dosing Duration.
Pen means the pre-filled cartridge pen device currently marketed by Licensee to administer via injection once daily formulations of the Licensee’s recombinant human PTH analog (1-34) rhPTH (1-34) or manufactured by Licensee to administer a placebo.
Product Patch means a micro-projection array which pierces through the outmost, the stratum corneum, layer of the skin and either in which the micro-projections are coated with a formulation containing PTH as an active pharmaceutical ingredient, to deliver such active pharmaceutical ingredient into or through the skin, in a passive, diffusion-mediated manner, or to form pathways for diffusion-mediated delivery of PTH as an active pharmaceutical ingredient into or through the skin, in each inclusive of an applicator device, API, patch and packaging. For purposes of clarity, the Product Patch shall include all dosage and timed release formulations of PTH.
Licensee currently markets Forteo®, a once-daily formulation of Licensee’s recombinant human PTH analog (1-34) rhPTH(1-34) administered by subcutaneous injection and approved in the United States for the treatment of severe osteoporosis.
FORTEO is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis. FORTEO is used to increase the bone mass in men with primary or hypogonadal osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO is used to treat both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.
IPSCIO Record ID: 273586
Licensor is knowledgeable in the development of drug specific oral and transdermal dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments.
Catapres-TTS (clonidine) transdermal therapeutic system is a square, tan adhesive patch containing an active blood-pressure-lowering medication. It is designed to deliver the drug into the body through the skin smoothly and consistently for one full week.
IPSCIO Record ID: 6128
IPSCIO Record ID: 570
The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.
Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.
